No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, along with its subsidiaries, primarily manufactures and markets traditional Chinese medicine, Western pharmaceuticals, and various healthcare products within the People's Republic of China. Its business activities are structured into two distinct divisions: Chinese Medicine and Western Medicine. The company's operations extend beyond its core offerings to include the production and distribution of Chinese, Western, and biological pharmaceutical items. It also engages in the wholesale and retail trade of medicines, biochemical pharmaceutical products, and everyday consumer goods, in addition to managing hospitals. Furthermore, Tianjin Pharmaceutical Da Ren Tang provides a comprehensive suite of services such as logistics, inventory management, equipment installation, and drug processing. It also offers pharmaceutical inspection, testing, and advisory services. In terms of its commercial model, the company supplies its proprietary branded medicinal products directly to wholesalers. Conversely, it acquires pharmaceuticals marketed under other brands from distributors, subsequently reselling these to other wholesale clients. Established in 1992 and based in Tianjin, People's Republic of China, the company was previously known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited before adopting its current name in May 2022.
www.jydrt.com.cnNo one on the platform currently holds 600329.SS.
No tracked institution reports a position in 600329.SS as of their last filing.
No one on the platform has traded 600329.SS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 34.4% | 28.2% | 21.5% | — | — | — |
| Rev. Growth % | -32.7% | -5.7% | ||||
| Profit Margin % | 43.3% | 21.5% | 15.0% | |||
| Free Cash Flow Margin % | 7.0% | 8.3% | 5.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $4.9B | +0.5% | $1.34 | $1.34–$1.34 | — | 1 |
| 2027 | $5.4B | +8.5% | $1.54 | $1.54–$1.54 | — | 1 |
| 2028 | $5.7B | +6.8% | $1.71 | $1.71–$1.71 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 600329.SSTianjin Pharmaceutical Da Ren Tang Group Corporation Limited | $34.00 | -0.23% | $19.4B | — |
| 000423.SZDong-E-E-Jiao Co.,Ltd. | $46.29 | +0.39% | $29.6B | — |
| 000513.SZLivzon Pharmaceutical Group Inc. | $26.62 | +0.15% | $23.6B | — |
| 000623.SZJilin Aodong Pharmaceutical Group Co., Ltd. | $17.37 | -0.17% | $20.8B | — |
| 002262.SZJiangsu Nhwa Pharmaceutical Co., Ltd. |
| $21.65 |
| -0.64% |
| $22.0B |
| — |
| 002773.SZChengdu Kanghong Pharmaceutical Group Co., Ltd | $19.13 | -0.16% | $17.6B | — |
| 600079.SSHumanwell Healthcare (Group) Co.,Ltd. | $18.50 | -0.22% | $30.2B | — |
Source: Financial Modeling Prep · peers by sector/industry